ACAD
$20.90
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Intraday
Recent News
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the company’s virtual CNS conference, with a focus on remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis (ADP), an ongoing Phase 2 program in Lewy body dementia psychosi
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot ACADIA Pharmaceuticals (ACAD) has attracted attention after a weak spell in the stock, with shares showing declines over the past week, month and past 3 months, despite a higher total return over the past year. For context, the company reports annual revenue of US$1,071.505m and net income of US$391.0m, supported by products focused on neurological and rare diseases, including treatments for Parkinson’s disease psychosis and Rett syndrome. See...
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead
ACADIA Pharmaceuticals (NASDAQ:ACAD) highlighted its growing commercial portfolio, upcoming clinical catalysts, and cash position during a presentation at the Citizens Life Sciences Conference, with remarks from CFO Mark Schneyer and Head of Clinical Development Srdjan Stankovic. Commercial portfol
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
JAZZ vs. ACAD: Which Stock Is the Better Value Option?